title: The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.
abstract: The modulation of DNA repair pathways for therapeutic benefit in cancer has now become a reality with the development of poly (ADP-ribose) polymerase inhibitors (PARPi). PARP is involved in single-strand DNA breaks, which in the presence of defective homologous recombination repair lead to double-strand DNA breaks, the most lethal form of DNA damage. These agents therefore may be the drugs of choice for BRCA mutant breast and ovarian cancers. PARPi result in synergistic antitumor effects when combined with cisplatin, temozolomide, topoisomerase inhibitors and ionizing radiation. The indications for PARPi lie beyond BRCA mutations and may include genomic and functional defects in DNA repair and damage response pathways. Several PARPi are in the clinical development phase at this time and, given the recent failure of a phase III clinical trial of iniparib in triple-negative breast cancer, the identification of structural and functional differences between these inhibitors becomes critical. Acquired resistance to PARPi is being noted and represents an important limitation in this field. A concise review of the literature in this field is presented.
authors.affiliation: Associate Professor, UT-MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: M
authors.initials: M
authors.lastname: Javle
authors.forename: N J
authors.initials: NJ
authors.lastname: Curtin
references.citation: Nature. 2005 Apr 14;434(7035):917-21
references.pmid: 15829967
references.citation: N Engl J Med. 2009 Jul 9;361(2):123-34
references.pmid: 19553641
references.citation: Clin Cancer Res. 2008 Dec 1;14(23):7917-23
references.pmid: 19047122
references.citation: Nature. 2005 Apr 14;434(7035):913-7
references.pmid: 15829966
references.citation: Cancer Res. 2009 Apr 15;69(8):3589-96
references.pmid: 19351835
references.citation: Nature. 2008 Feb 28;451(7182):1111-5
references.pmid: 18264088
references.citation: Nat Rev Cancer. 2004 Oct;4(10):814-9
references.pmid: 15510162
references.citation: Trends Biochem Sci. 1994 Apr;19(4):172-6
references.pmid: 8016868
references.citation: J Med Chem. 2009 Jan 22;52(2):514-23
references.pmid: 19143569
references.citation: Mol Cancer Ther. 2007 Mar;6(3):945-56
references.pmid: 17363489
references.citation: Cancer Res. 2010 Feb 15;70(4):1700-10
references.pmid: 20145144
references.citation: Nat Rev Cancer. 2010 Apr;10(4):293-301
references.pmid: 20200537
references.citation: J Thromb Thrombolysis. 2009 May;27(4):359-64
references.pmid: 18535785
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3319-24
references.pmid: 19064545
references.citation: Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):410-9
references.pmid: 14751510
references.citation: Clin Cancer Res. 2009 Dec 1;15(23):7277-90
references.pmid: 19934293
references.citation: Int J Mol Med. 2006 Feb;17(2):369-75
references.pmid: 16391839
references.citation: J Biol Chem. 2007 Jun 1;282(22):16441-53
references.pmid: 17428792
references.citation: Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):2783-8
references.pmid: 21270334
references.citation: Cancer Invest. 2009 Aug;27(7):756-63
references.pmid: 19440934
references.citation: Nat Rev Mol Cell Biol. 2006 Jul;7(7):517-28
references.pmid: 16829982
references.citation: Cancer Res. 2010 Aug 1;70(15):6268-76
references.pmid: 20631063
references.citation: Biochem Pharmacol. 2002 Feb 1;63(3):455-62
references.pmid: 11853696
references.citation: Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1188-97
references.pmid: 18954712
references.citation: Clin Cancer Res. 2009 Oct 1;15(19):6106-12
references.pmid: 19789326
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: Clin Cancer Res. 2010 Apr 15;16(8):2344-51
references.pmid: 20371688
references.citation: Clin Cancer Res. 2007 May 1;13(9):2728-37
references.pmid: 17473206
references.citation: J Clin Oncol. 2008 Aug 1;26(22):3785-90
references.pmid: 18591545
references.citation: Mol Cell Biochem. 1994 Sep;138(1-2):15-24
references.pmid: 7898458
references.citation: J Natl Cancer Inst. 2004 Jan 7;96(1):56-67
references.pmid: 14709739
references.citation: Eur J Cancer. 2006 Sep;42(14):2374-81
references.pmid: 16809031
references.citation: Lancet. 2010 Jul 24;376(9737):235-44
references.pmid: 20609467
references.citation: Cancer Res. 2006 Aug 15;66(16):8109-15
references.pmid: 16912188
references.citation: J Clin Oncol. 2010 Aug 1;28(22):3555-61
references.pmid: 20547991
references.citation: Mutat Res. 2000 Jun 30;460(1):1-15
references.pmid: 10856830
references.citation: Science. 2009 Sep 4;325(5945):1240-3
references.pmid: 19661379
references.citation: J Natl Cancer Inst. 2002 Jul 3;94(13):990-1000
references.pmid: 12096084
references.citation: J Natl Cancer Inst. 2011 Feb 16;103(4):334-46
references.pmid: 21183737
references.citation: Mol Cancer Ther. 2009 Feb;8(2):407-14
references.pmid: 19174557
references.citation: Biochem Pharmacol. 1995 Aug 25;50(5):705-14
references.pmid: 7669074
references.citation: Clin Cancer Res. 2011 Feb 15;17(4):783-91
references.pmid: 21097693
references.citation: J Clin Oncol. 2010 May 20;28(15):2512-9
references.pmid: 20406929
references.citation: Clin Cancer Res. 2010 Dec 1;16(23):5796-804
references.pmid: 21138871
references.citation: N Engl J Med. 2011 Jan 20;364(3):205-14
references.pmid: 21208101
references.citation: Pharmacol Rev. 2002 Sep;54(3):375-429
references.pmid: 12223530
references.citation: Nat Struct Mol Biol. 2009 Sep;16(9):923-9
references.pmid: 19680243
references.citation: J Med Chem. 2008 Oct 23;51(20):6581-91
references.pmid: 18800822
references.citation: J Biol Chem. 2002 Jun 21;277(25):23028-36
references.pmid: 11948190
references.citation: Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84
references.pmid: 18971340
references.citation: J Clin Oncol. 2009 Jun 1;27(16):2705-11
references.pmid: 19364967
references.citation: Cancer Res. 2008 Apr 15;68(8):2581-6
references.pmid: 18413725
references.citation: Haematologica. 2009 May;94(5):638-46
references.pmid: 19407318
references.citation: Nature. 2008 Feb 28;451(7182):1116-20
references.pmid: 18264087
references.citation: Clin Cancer Res. 2010 Dec 15;16(24):6159-68
references.pmid: 20802015
references.citation: Mol Cancer Ther. 2005 Sep;4(9):1364-8
references.pmid: 16170028
references.citation: Nat Struct Mol Biol. 2010 Jun;17(6):688-95
references.pmid: 20453858
references.citation: Eur J Cancer. 2008 Jun;44(9):1302-14
references.pmid: 18440222
references.citation: Cancer Res. 2010 Jul 1;70(13):5457-64
references.pmid: 20530668
references.citation: Mol Genet Genomics. 2011 Apr;285(4):325-40
references.pmid: 21409565
references.citation: J Med Chem. 2010 Jun 24;53(12):4561-84
references.pmid: 20364863
references.citation: Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3406-11
references.pmid: 21300883
references.citation: Mol Cancer Ther. 2010 Feb;9(2):347-57
references.pmid: 20124459
references.citation: Cell. 2010 Apr 16;141(2):243-54
references.pmid: 20362325